UKDTN launched its first Phase 1b Alzheimer’s trial, dosing the first patient in Europe and streamlining setup across sites, with further trials and collaborations in progress.  

On 3 December 2025, UKDTN convened the UK Industry Liaison Forum at CTAD 2025 in San Diego, bringing together global charities, international academic experts, and industry partners from over 20 pharma and biotech companies worldwide.

Over the past year, the UKDTN Coordinating Centre has grown exponentially, expanding to a dedicated team of 10 members to support the continued growth and delivery of the network.